1
|
Nguyen HD, Ngo HV, Lee BJ. Novel pH-Responsive Structural Rearrangement of Myristic Acid-Conjugated Quetiapine Nanosuspension for Enhanced Long-Acting Delivery Performance. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2024:e2405200. [PMID: 39225461 DOI: 10.1002/advs.202405200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/13/2024] [Revised: 08/17/2024] [Indexed: 09/04/2024]
Abstract
Quetiapine myristate (QM), an ester-bonded lipophilic prodrug of quetiapine (QTP), is synthesized and converted into an amphiphilic structure in acidic pH to trigger a novel self-assembled QM nanosuspension (QMN). Following injection, this QMN rearranges within physiological pH to form nanoaggregates in structure, resulting in enhanced physicochemical properties and in vivo therapeutic performance without an initial burst release. The 200-nm-sized QMN exhibits less invasive injection, higher drug content, and better storage stability profile than conventional poly(lactide-co-glycolide) (PLGA) nanosuspensions containing QTP or QM. Following a single intramuscular injection to beagle dogs (35 mg kg-1 QTP), QMN undergoes pH-responsive nanoaggregation to form the lipophilic prodrug, providing esterase-oriented sustained release for five weeks compared with the two-week period of PLGA nanosuspensions. Notably, QMN exhibits improved in vivo pharmacokinetic performance with long-acting delivery while minimizing issues associated with polymeric PLGA formulations, including the initial massive burst release, cellular toxicity, and adverse side effects. These results support the further development of QMN as a novel long-acting injectable to improve patient compliance and dosing frequency.
Collapse
Affiliation(s)
- Hy Dinh Nguyen
- Department of Pharmacy, College of Pharmacy, Ajou University, Suwon, 16499, Republic of Korea
| | - Hai Van Ngo
- Department of Pharmacy, College of Pharmacy, Ajou University, Suwon, 16499, Republic of Korea
| | - Beom-Jin Lee
- Department of Pharmacy, College of Pharmacy, Ajou University, Suwon, 16499, Republic of Korea
- Institute of Pharmaceutical Science and Technology, Ajou University, Suwon, 16499, Republic of Korea
| |
Collapse
|
2
|
Grönniger B, Kimpe K, Singh A, Sadowski G. Simultaneous Water Sorption and Crystallization in ASDs 1: Stability Studies Lasting for Two Years. Mol Pharm 2024; 21:957-969. [PMID: 38173336 DOI: 10.1021/acs.molpharmaceut.3c01056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2024]
Abstract
One way to increase the slow dissolution rate and the associated low bioavailability of newly developed active pharmaceutical ingredients (APIs) is to dissolve the API in a polymer, leading to a so-called amorphous solid dispersion (ASD). However, APIs are often supersaturated in ASDs and thus tend to crystallize during storage. The kinetics of the crystallization process is determined by the amount of water the ASD absorbs during storage at relative humidity (RH), storage temperature, polymer type, and the drug load of the ASD. Here, the crystallization kinetics and shelf life of spray-dried ASDs were investigated for ASDs consisting of nifedipine (NIF) or celecoxib (CCX) as the APIs and of poly(vinylpyrrolidone-co-vinyl acetate) or hydroxypropyl methylcellulose acetate succinate as polymers. Samples were stored over 2 years at different RHs covering conditions above and below the glass transition of the wet ASDs. Crystallization kinetics and onset time of the crystallization were qualitatively studied by using powder X-ray diffraction and microscopic inspection and were quantitatively determined by using differential scanning calorimetry. It was found that the NIF ASDs crystallize much faster than CCX ASDs at the same drug load and at the same storage conditions due to both higher supersaturation and higher molecular mobility in the NIF ASDs. Experimental data on crystallization kinetics were correlated using the Johnson-Mehl-Avrami-Kolmogorov equation. A detailed thermodynamic and kinetic modeling will be performed in Part 2 of this paper series.
Collapse
Affiliation(s)
- Birte Grönniger
- Department of Biochemical and Chemical Engineering, Laboratory of Thermodynamics, TU Dortmund University, Emil-Figge-Str. 70, D-44227 Dortmund, Germany
| | - Kristof Kimpe
- Janssen Pharmaceutica R&D, Turnhoutseweg 30, B-2340 Beerse, Belgium
| | - Abhishek Singh
- Janssen Pharmaceutica R&D, Turnhoutseweg 30, B-2340 Beerse, Belgium
| | - Gabriele Sadowski
- Department of Biochemical and Chemical Engineering, Laboratory of Thermodynamics, TU Dortmund University, Emil-Figge-Str. 70, D-44227 Dortmund, Germany
| |
Collapse
|
3
|
Sokol MB, Sokhraneva VA, Groza NV, Mollaeva MR, Yabbarov NG, Chirkina MV, Trufanova AA, Popenko VI, Nikolskaya ED. Thymol-Modified Oleic and Linoleic Acids Encapsulated in Polymeric Nanoparticles: Enhanced Bioactivity, Stability, and Biomedical Potential. Polymers (Basel) 2023; 16:72. [PMID: 38201737 PMCID: PMC10781094 DOI: 10.3390/polym16010072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Revised: 12/20/2023] [Accepted: 12/22/2023] [Indexed: 01/12/2024] Open
Abstract
Unsaturated fatty acids, such as oleic acid (OA) and linoleic acid (LA), are promising antimicrobial and cytostatic agents. We modified OA and LA with thymol (TOA and TLA, respectively) to expand their bioavailability, stability, and possible applications, and encapsulated these derivatives in polymeric nanoparticles (TOA-NPs and TLA-NPs, respectively). Prior to synthesis, we performed mathematical simulations with PASS and ADMETlab 2.0 to predict the biological activity and pharmacokinetics of TOA and TLA. TOA and TLA were synthesized via esterification in the presence of catalysts. Next, we formulated nanoparticles using the single-emulsion solvent evaporation technique. We applied dynamic light scattering, Uv-vis spectroscopy, release studies under gastrointestinal (pH 1.2-6.8) and blood environment simulation conditions (pH 7.4), and in vitro biological activity testing to characterize the nanoparticles. PASS revealed that TOA and TLA have antimicrobial and anticancer therapeutic potential. ADMETlab 2.0 provided a rationale for TOA and TLA encapsulation. The nanoparticles had an average size of 212-227 nm, with a high encapsulation efficiency (71-93%), and released TOA and TLA in a gradual and prolonged mode. TLA-NPs possessed higher antibacterial activity against B. cereus and S. aureus and pronounced cytotoxic activity against MCF-7, K562, and A549 cell lines compared to TOA-NPs. Our findings expand the biomedical application of fatty acids and provide a basis for further in vivo evaluation of designed derivatives and formulations.
Collapse
Affiliation(s)
- Maria B. Sokol
- N.M. Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, 119334 Moscow, Russia; (M.R.M.); (N.G.Y.); (M.V.C.); (A.A.T.)
| | - Vera A. Sokhraneva
- N.A. Preobrazhensky Department of Chemistry and Technology of Biologically Active Compounds, Medicinal and Organic Chemistry, M.V. Lomonosov Institute of Fine Chemical Technologies, MIREA—Russian Technological University, 119571 Moscow, Russia; (V.A.S.); (N.V.G.)
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 11999 Moscow, Russia;
| | - Nataliya V. Groza
- N.A. Preobrazhensky Department of Chemistry and Technology of Biologically Active Compounds, Medicinal and Organic Chemistry, M.V. Lomonosov Institute of Fine Chemical Technologies, MIREA—Russian Technological University, 119571 Moscow, Russia; (V.A.S.); (N.V.G.)
| | - Mariia R. Mollaeva
- N.M. Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, 119334 Moscow, Russia; (M.R.M.); (N.G.Y.); (M.V.C.); (A.A.T.)
| | - Nikita G. Yabbarov
- N.M. Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, 119334 Moscow, Russia; (M.R.M.); (N.G.Y.); (M.V.C.); (A.A.T.)
| | - Margarita V. Chirkina
- N.M. Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, 119334 Moscow, Russia; (M.R.M.); (N.G.Y.); (M.V.C.); (A.A.T.)
| | - Anna A. Trufanova
- N.M. Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, 119334 Moscow, Russia; (M.R.M.); (N.G.Y.); (M.V.C.); (A.A.T.)
| | - Vladimir I. Popenko
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 11999 Moscow, Russia;
| | - Elena D. Nikolskaya
- N.M. Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, 119334 Moscow, Russia; (M.R.M.); (N.G.Y.); (M.V.C.); (A.A.T.)
| |
Collapse
|
4
|
Rashid H, Lucas H, Busse K, Kressler J, Mäder K, Trutschel ML. Development of Poly(sorbitol adipate)- g-poly(ethylene glycol) Mono Methyl Ether-Based Hydrogel Matrices for Model Drug Release. Gels 2023; 10:17. [PMID: 38247740 PMCID: PMC10815636 DOI: 10.3390/gels10010017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2023] [Revised: 12/19/2023] [Accepted: 12/19/2023] [Indexed: 01/23/2024] Open
Abstract
Hydrogels were prepared by Steglich esterification and by crosslinking pre-synthesized poly(sorbitol adipate)-graft-poly(ethylene glycol) mono methyl ether (PSA-g-mPEG) using different-chain-length-based disuccinyl PEG. PSA and PSA-g-mPEG were investigated for polymer degradation as a function of time at different temperatures. PSA-g-mPEG hydrogels were then evaluated for their most crucial properties of swelling that rendered them suitable for many pharmaceutical and biomedical applications. Hydrogels were also examined for their Sol-Gel content in order to investigate the degree of cross-linking. Physical structural parameters of the hydrogels were theoretically estimated using the modified Flory-Rehner theory to obtain approximate values of polymer volume fraction, the molecular weight between two crosslinks, and the mesh size of the hydrogels. X-ray diffraction was conducted to detect the presence or absence of crystalline regions in the hydrogels. PSA-g-mPEG hydrogels were then extensively examined for higher and lower molecular weight solute release through analysis by fluorescence spectroscopy. Finally, the cytotoxicity of the hydrogels was also investigated using a resazurin reduction assay. Experimental results show that PSA-g-mPEG provides an option as a biocompatible polymer to be used for pharmaceutical applications.
Collapse
Affiliation(s)
- Haroon Rashid
- Institute of Pharmacy, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany
- Department of Chemistry, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany
| | - Henrike Lucas
- Institute of Pharmacy, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany
| | - Karsten Busse
- Department of Chemistry, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany
| | - Jörg Kressler
- Department of Chemistry, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany
| | - Karsten Mäder
- Institute of Pharmacy, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany
| | - Marie-Luise Trutschel
- Institute of Pharmacy, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany
| |
Collapse
|
5
|
Bendicho-Lavilla C, Seoane-Viaño I, Santos-Rosales V, Díaz-Tomé V, Carracedo-Pérez M, Luzardo-Álvarez AM, García-González CA, Otero-Espinar FJ. Intravitreal implants manufactured by supercritical foaming for treating retinal diseases. J Control Release 2023; 362:342-355. [PMID: 37633363 DOI: 10.1016/j.jconrel.2023.08.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 08/18/2023] [Accepted: 08/23/2023] [Indexed: 08/28/2023]
Abstract
Chronic retinal diseases, such as age-related macular degeneration (AMD), are a major cause of global visual impairment. However, current treatment methods involving repetitive intravitreal injections pose financial and health burdens for patients. The development of controlled drug release systems, particularly for biological drugs, is still an unmet need in prolonging drug release within the vitreous chamber. To address this, green supercritical carbon dioxide (scCO2) foaming technology was employed to manufacture porous poly(lactic-co-glycolic acid) (PLGA)-based intravitreal implants loaded with dexamethasone. The desired implant dimensions were achieved through 3D printing of customised moulds. By varying the depressurisation rates during the foaming process, implants with different porosities and dexamethasone release rates were successfully obtained. These implants demonstrated controlled drug release for up to four months, surpassing the performance of previously developed implants. In view of the positive results obtained, a pilot study was conducted using the monoclonal antibody bevacizumab to explore the feasibility of this technology for preparing intraocular implants loaded with biologic drug molecules. Overall, this study presents a greener and more sustainable alternative to conventional implant manufacturing techniques, particularly suited for drugs that are susceptible to degradation under harsh conditions.
Collapse
Affiliation(s)
- Carlos Bendicho-Lavilla
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, and Materials Institute iMATUS, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain; Paraquasil Group (GI-2109), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain
| | - Iria Seoane-Viaño
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, and Materials Institute iMATUS, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain; Paraquasil Group (GI-2109), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Víctor Santos-Rosales
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Materials Institute iMATUS and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Victoria Díaz-Tomé
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, and Materials Institute iMATUS, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain; Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain
| | - María Carracedo-Pérez
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Materials Institute iMATUS and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Asteria M Luzardo-Álvarez
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, and Materials Institute iMATUS, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain; Paraquasil Group (GI-2109), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain
| | - Carlos A García-González
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Materials Institute iMATUS and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Francisco J Otero-Espinar
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, and Materials Institute iMATUS, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain; Paraquasil Group (GI-2109), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
| |
Collapse
|
6
|
Bezerra GSN, De Lima GG, Colbert DM, Halligan E, Geever J, Geever L. Micro-Injection Moulding of PEO/PCL Blend–Based Matrices for Extended Oral Delivery of Fenbendazole. Pharmaceutics 2023; 15:pharmaceutics15030900. [PMID: 36986761 PMCID: PMC10051197 DOI: 10.3390/pharmaceutics15030900] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 03/01/2023] [Accepted: 03/03/2023] [Indexed: 03/12/2023] Open
Abstract
Fenbendazole (FBZ) is a broad-spectrum anthelmintic administered orally to ruminants; nevertheless, its poor water solubility has been the main limitation to reaching satisfactory and sustained levels at the site of the target parasites. Hence, the exploitation of hot-melt extrusion (HME) and micro-injection moulding (µIM) for the manufacturing of extended-release tablets of plasticised solid dispersions of poly(ethylene oxide) (PEO)/polycaprolactone (PCL) and FBZ was investigated due to their unique suitability for semi-continuous manufacturing of pharmaceutical oral solid dosage forms. High-performance liquid chromatography (HPLC) analysis demonstrated a consistent and uniform drug content in the tablets. Thermal analysis using differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) suggested the amorphous state of the active ingredient, which was endorsed by powder X-ray diffraction spectroscopy (pXRD). Fourier transform infrared spectroscopy (FTIR) analysis did not display any new peak indicative of either a chemical interaction or degradation. Scanning electron microscopy (SEM) images showed smoother surfaces and broader pores as we increased the PCL content. Electron-dispersive X-ray spectroscopy (EDX) revealed that the drug was homogeneously distributed within the polymeric matrices. Drug release studies attested that all moulded tablets of amorphous solid dispersions improved the drug solubility, with the PEO/PCL blend–based matrices showing drug release by Korsmeyer–Peppas kinetics. Thus, HME coupled with µIM proved to be a promising approach towards a continuous automated manufacturing process for the production of oral solid dispersions of benzimidazole anthelmintics to grazing cattle.
Collapse
Affiliation(s)
- Gilberto S. N. Bezerra
- PRISM Research Institute, Technological University of the Shannon: Midlands Midwest, N37HD68 Athlone, Ireland
- Correspondence: (G.S.N.B.); (L.G.)
| | - Gabriel G. De Lima
- PRISM Research Institute, Technological University of the Shannon: Midlands Midwest, N37HD68 Athlone, Ireland
- Programa de Pós-Graduação em Engenharia e Ciência dos Materiais—PIPE, Universidade Federal do Paraná, Curitiba 81531-980, Brazil
| | - Declan M. Colbert
- PRISM Research Institute, Technological University of the Shannon: Midlands Midwest, N37HD68 Athlone, Ireland
| | - Elaine Halligan
- PRISM Research Institute, Technological University of the Shannon: Midlands Midwest, N37HD68 Athlone, Ireland
| | - Joseph Geever
- PRISM Research Institute, Technological University of the Shannon: Midlands Midwest, N37HD68 Athlone, Ireland
| | - Luke Geever
- PRISM Research Institute, Technological University of the Shannon: Midlands Midwest, N37HD68 Athlone, Ireland
- Correspondence: (G.S.N.B.); (L.G.)
| |
Collapse
|
7
|
Dümichen A, Lucas H, Trutschel ML, Mäder K. Development and Characterization of Novel In-Situ-Forming Oleogels. Pharmaceutics 2023; 15:pharmaceutics15010254. [PMID: 36678883 PMCID: PMC9867396 DOI: 10.3390/pharmaceutics15010254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Revised: 12/30/2022] [Accepted: 01/09/2023] [Indexed: 01/13/2023] Open
Abstract
PLGA-based in situ forming implants (ISFI) often require a high amount of potentially toxic solvents such as N methyl-Pyrrolidone (NMP). The aim of the present study was to develop lipid in-situ-forming oleogels (ISFOs) as alternative delivery systems. 12-Hydroxystearic acid (12-HSA) was selected as the oleogelling agent and three different oleoformulations were investigated: (a) 12-HSA, peanut oil (PO), NMP; (b) 12-HSA, medium-chain triglycerides (MCT), ethanol; (c) 12-HSA, isopropyl myristate (IPM), ethanol. The effects of the 12-HSA concentration, preparation method, and composition on the mechanical stability were examined using a texture analysis and oscillating rheology. The texture analysis was used to obtain information on the compression strength. The amplitude sweeps were analyzed to provide information on the gel strength and the risk of brittle fractures. The frequency sweeps allowed insights into the long-term stability and risk of syneresis. The syringeability of the ISFOs was tested, along with their acute and long-term cytotoxicity in vitro. The developed ISFOs have the following advantages: (1) the avoidance of highly acidic degradation products; (2) low amounts of organic solvents required; (3) low toxicity; (4) low injection forces, even with small needle sizes. Therefore, ISFOs are promising alternatives to the existing polymer/NMP-based ISFIs.
Collapse
|
8
|
Pei Y, Wang J, Khaliq NU, Meng F, Oucherif KA, Xue J, Horava SD, Cox AL, Richard CA, Swinney MR, Park K, Yeo Y. Development of poly(lactide-co-glycolide) microparticles for sustained delivery of meloxicam. J Control Release 2023; 353:823-831. [PMID: 36521690 DOI: 10.1016/j.jconrel.2022.12.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Revised: 12/07/2022] [Accepted: 12/08/2022] [Indexed: 12/23/2022]
Abstract
Poly(lactide-co-glycolide) (PLGA) polymers have been widely used for drug delivery due to their biodegradability and biocompatibility. One of the objectives of encapsulating a drug in PLGA microparticles (MPs) is to achieve an extended supply of the drug through sustained release, which can range from weeks to months. Focusing on the applications needing a relatively short-term delivery, we investigated formulation strategies to achieve a drug release from PLGA MPs for two weeks, using meloxicam as a model compound. PLGA MPs produced by the traditional oil/water (O/W) single emulsion method showed only an initial burst release with minimal increase in later-phase drug release. Alternatively, encapsulating meloxicam as solid helped reduce the initial burst release. The inclusion of magnesium hydroxide [Mg(OH)2] enhanced later-phase drug release by neutralizing the developing acidity that limited the drug dissolution. The variation of solid meloxicam and Mg(OH)2 quantities allowed for flexible control of meloxicam release, yielding MPs with distinct in vitro release kinetics. When subcutaneously injected into rats, the MPs with relatively slow in vitro drug release kinetics showed in vivo drug absorption profiles consistent with in vitro trend. However, the MPs that rapidly released meloxicam showed an attenuated in vivo absorption, suggesting premature precipitation of fast-released meloxicam. In summary, this study demonstrated the feasibility of controlling drug release from the PLGA MPs over weeks based on the physical state of the encapsulated drug and the inclusion of Mg(OH)2 to neutralize the microenvironmental pH of the MPs.
Collapse
Affiliation(s)
- Yihua Pei
- Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA
| | - Jianping Wang
- Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA
| | - Nisar Ul Khaliq
- Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA
| | - Fanfei Meng
- Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA
| | | | - Jie Xue
- Eli Lilly and Company, 893 Delaware Street, Indianapolis, IN 46225, USA
| | - Sarena D Horava
- Eli Lilly and Company, 450 Kendall Street, Cambridge, MA 02142, USA
| | - Amy L Cox
- Eli Lilly and Company, 893 Delaware Street, Indianapolis, IN 46225, USA
| | - Coralie A Richard
- Eli Lilly and Company, 893 Delaware Street, Indianapolis, IN 46225, USA
| | - Monica R Swinney
- Eli Lilly and Company, 450 Kendall Street, Cambridge, MA 02142, USA
| | - Kinam Park
- Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA; Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA
| | - Yoon Yeo
- Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA; Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA.
| |
Collapse
|
9
|
Implications of changes in physical state of drugs in poly(lactide-co-glycolide) matrices upon exposure to moisture and release medium. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.104115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
10
|
Bassand C, Freitag J, Benabed L, Verin J, Siepmann F, Siepmann J. PLGA implants for controlled drug release: Impact of the diameter. Eur J Pharm Biopharm 2022; 177:50-60. [PMID: 35659920 DOI: 10.1016/j.ejpb.2022.05.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 05/24/2022] [Accepted: 05/27/2022] [Indexed: 11/17/2022]
Abstract
The aim of this study was to better understand the importance of the diameter of poly(lactic-co-glycolic acid) (PLGA)-based implants on system performance, in particular the control of drug release. Different types of ibuprofen-loaded implants were prepared by hot melt extrusion using a Leistritz Nano 16 twin-screw extruder. Drug release was measured in well agitated phosphate buffer pH7.4 bulk fluid and in agarose gels in Eppendorf tubes or transwell plates. Dynamic changes in the implants' dry & wet mass, volume, polymer molecular weight as well as inner & outer morphology were monitored using gravimetric analysis, optical macroscopy, gel permeation chromatography and scanning electron microscopy. The physical states of the drug and polymer were determined by DSC. Also pH changes in the release medium were investigated. Irrespective of the type of experimental set-up, the resulting absolute and relative drug release rates decreased with increasing implant diameter (0.7 to 2.8 mm). Bi-phasic drug release was observed in all cases from the monolithic solutions (ibuprofen was dissolved in the polymer): A zero order release phase was followed by a final, rapid drug release phase (accounting for 80-90% of the total drug dose). The decrease in the relative drug release rate with increasing system diameter can be explained by the increase in the diffusion pathway lengths to be overcome. Interestingly, also the onset of the final rapid drug release phase was delayed with increasing implant diameter. This can probably be attributed to the higher mechanical stability of thicker devices, offering more resistance to substantial entire system swelling.
Collapse
Affiliation(s)
- C Bassand
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Freitag
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - L Benabed
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Verin
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - F Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France.
| |
Collapse
|
11
|
Bassand C, Benabed L, Verin J, Danede F, Lefol L, Willart J, Siepmann F, Siepmann J. Hot melt extruded PLGA implants loaded with ibuprofen: How heat exposure alters the physical drug state. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103432] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
12
|
Truong HAT, Mothe SR, Min JL, Tan HM, Jackson AW, Nguyen DT, Ye DKJ, Kanaujia P, Thoniyot P, Dang TT. Immuno-modulatory Effects of Microparticles Formulated from Degradable Polystyrene Analogue. Macromol Biosci 2022; 22:e2100472. [PMID: 35261175 DOI: 10.1002/mabi.202100472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Indexed: 11/11/2022]
Abstract
Environmental accumulation of non-degradable polystyrene (PS) microparticles from plastic waste poses potential adverse impact on marine life and human health. Herein, we formulate microparticles from a degradable polystyrene analogue (dePS) and comprehensively evaluate their immuno-modulatory characteristics. Both dePS copolymer and microparticles are chemically degradable under accelerated hydrolytic condition. In vitro studies show that dePS microparticles are non-toxic to three immortalized cell lines. While dePS microparticles do not induce macrophage polarization in vitro, dePS microparticles induce in vivo upregulation of both pro-inflammatory and anti-inflammatory biomarkers in immuno-competent mice, suggesting the coexistence of mixed phenotypes of macrophages in the host immune response to these microparticles. Interestingly, on day 7 post-injection, dePS microparticles induce a lower level of several immuno-modulatory biomarkers (MMPs activity, TNF-α, and arginase activity) compared to that of reference poly(lactic-co-glycolic acid) PLGA microparticles. Remarkably, compared to PS microparticles, dePS microparticles exhibit similar in vitro and in vivo bioactivity while acquiring additional chemical degradability. Overall, our research gains new insights into the host immune response to dePS microparticles and suggests that this degradable polystyrene analogue might be explored as an alternative material choice for biomedical and consumer care applications. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Hong Anh T Truong
- School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Avenue, Singapore, 637459, Singapore
| | - Srinivasa Reddy Mothe
- Institute of Chemical and Engineering Sciences (ICES), Agency for Science, Technology and Research (ASTAR), 1 Pesek Road, Jurong Island, Singapore, 627833, Singapore
| | - Jaclyn Lee Min
- School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Avenue, Singapore, 637459, Singapore
| | - Hui Min Tan
- School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Avenue, Singapore, 637459, Singapore
| | - Alexander W Jackson
- Institute of Chemical and Engineering Sciences (ICES), Agency for Science, Technology and Research (ASTAR), 1 Pesek Road, Jurong Island, Singapore, 627833, Singapore
| | - Dang Tri Nguyen
- School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Avenue, Singapore, 637459, Singapore
| | - Danson Kwong Jia Ye
- School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Avenue, Singapore, 637459, Singapore
| | - Parijat Kanaujia
- Institute of Chemical and Engineering Sciences (ICES), Agency for Science, Technology and Research (ASTAR), 1 Pesek Road, Jurong Island, Singapore, 627833, Singapore
| | - Praveen Thoniyot
- Institute of Chemical and Engineering Sciences (ICES), Agency for Science, Technology and Research (ASTAR), 1 Pesek Road, Jurong Island, Singapore, 627833, Singapore
| | - Tram Thuy Dang
- School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Avenue, Singapore, 637459, Singapore
| |
Collapse
|
13
|
An in vitro gel-based system for characterizing and predicting the long-term performance of PLGA in situ forming implants. Int J Pharm 2021; 609:121183. [PMID: 34653562 DOI: 10.1016/j.ijpharm.2021.121183] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Revised: 10/03/2021] [Accepted: 10/08/2021] [Indexed: 10/20/2022]
Abstract
In situ forming implants are exposed to an extracellular matrix resembling a gel rather than aqueous solution upon subcutaneous administration. The aim of study was to develop a gel-based release testing system for characterizing the long-term in vitro behavior of in situ forming implants. The gel-based system consisted of an agarose gel mimicking the subcutaneous injection site and a receiver layer comprising phosphate buffer. Poly(D,L-lactide-co-glycolide) in situ forming implants containing leuprolide acetate as the model peptide and N-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide (DMSO) or triacetin as co-solvent were investigated. The gel-based release testing system discriminated between the formulations. Accelerated release data obtained at elevated temperatures were able to predict real-time release applying the Arrhenius equation. Monitoring of the microenvironmental pH of the implants was performed by UV-Vis imaging in the gel-based system at 50 °C. A pH drop (from pH 7.4 to 6.7 for the NMP and DMSO implants, to pH 5.5 for the triacetin implants) within the first day was observed, followed by an increase to pH ∼7.4. The gel-based system coupled with UV imaging offered opportunity for detailed evaluation and prediction of the in vitro performance of long-acting injectables, facilitating future development of in situ depot forming delivery systems.
Collapse
|
14
|
Ferrari G, Thives Mello A, Melo G, de Mello Roesler CR, Salmoria GV, de Souza Pinto LP, de Mello Gindri I, Gindri M. Polymeric implants with drug-releasing capabilities: a mapping review of laboratory research. Drug Dev Ind Pharm 2021; 47:1535-1545. [PMID: 35171071 DOI: 10.1080/03639045.2022.2043354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
PURPOSE To provide a systematic map of the nature and extent of preclinical research concerning drug-releasing polymeric implants. SIGNIFICANCE By summarizing available data, this mapping review can guide the development of new drug-delivery devices. METHODS In-vitro studies assessing drug-delivery implants were reviewed. A study protocol was registered at Open Science Framework. The association of polymers with prominent drugs, manufacturing processes, geometries, treatments, and anatomical locations was assessed using the VOSviewer software. The release periods were also evaluated. RESULTS A total of 423 articles, published between 1975 and 2020, were included and grouped into a framework with nine main categories. More than half of studies were published between 2010 and 2020. Among 201 individual polymers or combinations, the most investigated were PLGA, PCL, PLA, Silicone (SIL), EVA, and PU. Similarly, from 232 individual drugs or combinations, the most prominent were dexamethasone (DEX; anti-inflammatory), paclitaxel (PTX; anticancer), fluoruracil (anticancer), ciprofloxacin (CFX) hydrochloride (antibiotic), and gentamicin (GS; antibiotic). A total of 51 manufacturing processes were encountered, of which the most reported were solvent evaporation, compression molding (CM), extrusion (EX), electrospinning (ELS), and melt molding (MM). Among 38 implant geometries, cylinder (CIL) was the most prominent, followed by disk, square film, circular film (FCIR), and undefined film. Release times varied greatly, although the majority of articles ranged between 5 and 300 d. CONCLUSIONS Drug-delivery implants were highly heterogeneous due to its applicability for multiple health conditions. Most implants were made of PLGA and most drugs assessed presented anti-inflammatory, antibiotic, or anticancer effects. Solvent evaporation and CIL were the most prominent manufacturing process and geometry, respectively.
Collapse
Affiliation(s)
- Gustavo Ferrari
- Iaso Biodelivery Fabricação de Dispositivos com Liberação de Fármacos LTDA, Florianópolis, Brazil.,Mechanical Engineering Department, Biomechanical Engineering Laboratory, University Hospital and Federal University of Santa Catarina (UFSC), Florianópolis, Brazil
| | - Arthur Thives Mello
- Postgraduate Program in Nutrition, Federal University of Santa Catarina (UFSC), Florianópolis, Brazil
| | - Gilberto Melo
- Postgraduate Program in Dentistry, Federal University of Santa Catarina (UFSC), Florianópolis, Brazil
| | - Carlos Rodrigo de Mello Roesler
- Mechanical Engineering Department, Biomechanical Engineering Laboratory, University Hospital and Federal University of Santa Catarina (UFSC), Florianópolis, Brazil
| | - Gean Vitor Salmoria
- Mechanical Engineering Department, Biomechanical Engineering Laboratory, University Hospital and Federal University of Santa Catarina (UFSC), Florianópolis, Brazil.,Mechanical Engineering Department., NIMMA - Núcleo de Inovação em Moldagem e Manufatura Aditiva, Federal University of Santa Catarina (UFSC), Florianópolis, Brazil
| | | | - Izabelle de Mello Gindri
- Iaso Biodelivery Fabricação de Dispositivos com Liberação de Fármacos LTDA, Florianópolis, Brazil.,Bio meds Pharmaceutica LTDA, Florianópolis, Brazil
| | - Mello Gindri
- Iaso Biodelivery Fabricação de Dispositivos com Liberação de Fármacos LTDA, Florianópolis, Santa Catarina, Brazil.,Bio meds Pharmaceutica LTDA, Florianópolis, Santa Catarina, Brazil
| |
Collapse
|
15
|
Maturavongsadit P, Shrivastava R, Sykes C, Cottrell ML, Montgomery SA, Kashuba ADM, Rahima Benhabbour S. Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs. Int J Pharm 2021; 605:120844. [PMID: 34216767 DOI: 10.1016/j.ijpharm.2021.120844] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 06/10/2021] [Accepted: 06/27/2021] [Indexed: 12/12/2022]
Abstract
Lack of adherence is a key barrier to a successful human immunodeficiency virus (HIV) treatment and prevention. We report on an ultra-long-acting (ULA) biodegradable polymeric solid implant (PSI) that can accommodate one or more antiretrovirals (e.g., dolutegravir (DTG) and rilpivirine (RPV)) at translatable human doses (65% wt.) in a single implant. PSIs are fabricated using a three-step process: (a) phase inversion of a drug/polymer solution to form an initial in-situ forming solid implant, (b) micronization of dried drug-loaded solid implants, and (c) compression of the micronized drug-loaded solid powder to generate the PSI. DTG and RPV can be pre-combined in a single PLGA-based solution to make dual-drug PSI; or formulated individually in PLGA-based solutions to generate separate micronized powders and form a bilayer dual-drug PSI. Results showed that in a single or bilayer dual-drug PSI, DTG and RPV exhibited physicochemical properties similar to their pure drug analogues. PSIs were well tolerated in vivo and effectively delivered drug(s) over 180 days with concentrations above 4× PA-IC90 after a single subcutaneous administration. While biodegradable and do not require removal, these PSIs can safely be removed to terminate the treatment if required. The versatility of this technology makes it attractive as an ULA drug delivery platform for HIV and various therapeutic applications.
Collapse
Affiliation(s)
- Panita Maturavongsadit
- Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Roopali Shrivastava
- Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Craig Sykes
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Mackenzie L Cottrell
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | | | - Angela D M Kashuba
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - S Rahima Benhabbour
- Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
| |
Collapse
|
16
|
Development of mAb-loaded 3D-printed (FDM) implantable devices based on PLGA. Int J Pharm 2021; 597:120337. [PMID: 33549812 DOI: 10.1016/j.ijpharm.2021.120337] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Revised: 01/25/2021] [Accepted: 01/30/2021] [Indexed: 01/21/2023]
Abstract
The main objective of this work was to explore the feasibility to print monoclonal antibody (mAb)-loaded implantable systems using fused-deposition modelling (FDM) to build complex dosage form designs. Indeed, to our knowledge, this work is the first investigation of mAb-loaded devices using FDM. To make this possible, different steps were developed and optimized. A mAb solution was stabilized using trehalose (TRE), sucrose (SUC), hydroxypropyl-β-cyclodextrin (HP-β-CD), sorbitol or inulin (INU) in order to be spray dried (SD). Printable filaments were then made of poly(lactide-co-glycolide) (PLGA) and mAb powder (15% w/w) using hot melt extrusion (HME). The FDM process was optimized to print these filaments without altering the mAb stability. TRE was selected and associated to L-leucine (LEU) to increase the mAb stability. The stability was then evaluated considering high and low molecular weight species levels. The mAb-based devices were well-stabilized with the selected excipients during both the HME and the FDM processes. The 3D-printed devices showed sustained-release profiles with a low burst effect. The mAb-binding capacity was preserved up to 70% following the whole fabrication process. These promising results demonstrate that FDM could be used to produce mAb-loaded devices with good stability, affinity and sustained-release profiles of the mAb.
Collapse
|
17
|
Engineering microenvironment of biodegradable polyester systems for drug stability and release control. Ther Deliv 2021; 12:37-54. [PMID: 33397135 DOI: 10.4155/tde-2020-0113] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Polymeric systems made of poly(lactic acid) or poly(lactic-co-glycolic acid) are widely used for long-term delivery of small and large molecules. The advantages of poly(lactic acid)/poly(lactic-co-glycolic acid) systems include biodegradability, safety and a long history of use in US FDA-approved products. However, as drugs delivered by the polymeric systems and their applications become more diverse, the significance of microenvironment change of degrading systems on long-term drug stability and release kinetics has gained renewed attention. In this review, we discuss various issues experienced with acidifying microenvironment of biodegradable polymer systems and approaches to overcome the detrimental effects of polymer degradation on drug stability and release control.
Collapse
|
18
|
Lehner E, Liebau A, Syrowatka F, Knolle W, Plontke SK, Mäder K. Novel biodegradable Round Window Disks for inner ear delivery of dexamethasone. Int J Pharm 2020; 594:120180. [PMID: 33338566 DOI: 10.1016/j.ijpharm.2020.120180] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Revised: 12/10/2020] [Accepted: 12/11/2020] [Indexed: 12/20/2022]
Abstract
Drug delivery to the inner ear is an important and very challenging field. The cochlea is protected by several barriers that need to be overcome in the drug delivery process. Local drug delivery can avoid undesirable side effects arising from systemic drug delivery. We developed a biodegradable dexamethasone-loaded Round Window (RW) Disk based on poly(D,L-lactic-co-glycolic acid) (PLGA) for local drug therapy to the inner ear by RW membrane administration by a film-casting method. The optimal drying time was characterized by thermogravimetric analysis and differential scanning calorimetry. In addition, the mass and polymer degradation over time of drug release was measured in vitro showing a total mass loss of 70% after 3 weeks. Dexamethasone release was determined by a RW model setup using a polyethylene terephthalate membrane. We achieved a controlled release over 52 days. Ex vivo implantation of a RW Disk onto a guinea pig RW membrane indicated well-fitting properties of the drug delivery device leading to a close surface contact with the membrane and the successful proof of concept. The developed RW Disks could be new and promising drug delivery device to achieve effective local drug delivery to the inner ear for an extended time.
Collapse
Affiliation(s)
- E Lehner
- Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - A Liebau
- Department of Otorhinolaryngology-Head and Neck Surgery, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - F Syrowatka
- Interdisciplinary Center of Materials Science, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
| | - W Knolle
- Leibniz Institute of Surface Engineering (IOM), Leipzig, Germany
| | - S K Plontke
- Department of Otorhinolaryngology-Head and Neck Surgery, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - K Mäder
- Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
| |
Collapse
|
19
|
Kožák J, Rabišková M, Lamprecht A. In-vitro drug release testing of parenteral formulations via an agarose gel envelope to closer mimic tissue firmness. Int J Pharm 2020; 594:120142. [PMID: 33326826 DOI: 10.1016/j.ijpharm.2020.120142] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2020] [Revised: 11/10/2020] [Accepted: 11/28/2020] [Indexed: 01/20/2023]
Abstract
Current in vitro drug-release testing of the sustained-release parenterals represents the in vivo situation insufficiently. In this work, a thin agarose hydrogel layer surrounding the tested dosage form was proposed to mimic the tissue. The method was applied on implantable formulations of different geometries (films, microspheres, and cylindrical implants); prepared from various polymers (several Resomer® grades or ethyl cellulose) and loaded with different model drugs: flurbiprofen, lidocaine or risperidone. The hydrogel layer did not possess any retarding effect on the released drug and acted as a physical restriction to swelling and/or plastic deformation of the tested dosage forms. This led to a different surface area available for drug-release compared with testing in release medium alone and correspondingly to significantly different release profiles of the majority of the formulations obtained between the two methods (e.g. t50% = 18 days in pure release medium vs. t50% = 26 days in gel-setup for risperidone loaded Resomer® 503 H films or t50% = 7 days vs. t50% = 19 days for risperidone loaded Resomer® 503 H microspheres). The limited space for swelling and the rigidity of the agarose gel might mimic the tight encapsulation of the dosage form in the tissue better than the conventional liquid medium.
Collapse
Affiliation(s)
- Jan Kožák
- Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, Gerhard-Domagk-Straße 3, 53121 Bonn, Germany; Department of Pharmaceutical Technology, Faculty of Pharmacy, Charles University, Akademika Heyrovskeho 1203/8, 500 05 Hradec Kralove, Czech Republic
| | - Miloslava Rabišková
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Charles University, Akademika Heyrovskeho 1203/8, 500 05 Hradec Kralove, Czech Republic
| | - Alf Lamprecht
- Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, Gerhard-Domagk-Straße 3, 53121 Bonn, Germany.
| |
Collapse
|
20
|
Marante T, Viegas C, Duarte I, Macedo AS, Fonte P. An Overview on Spray-Drying of Protein-Loaded Polymeric Nanoparticles for Dry Powder Inhalation. Pharmaceutics 2020; 12:E1032. [PMID: 33137954 PMCID: PMC7692719 DOI: 10.3390/pharmaceutics12111032] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Revised: 10/22/2020] [Accepted: 10/26/2020] [Indexed: 11/16/2022] Open
Abstract
The delivery of therapeutic proteins remains a challenge, despite recent technological advances. While the delivery of proteins to the lungs is the gold standard for topical and systemic therapy through the lungs, the issue still exists. While pulmonary delivery is highly attractive due to its non-invasive nature, large surface area, possibility of topical and systemic administration, and rapid absorption circumventing the first-pass effect, the absorption of therapeutic proteins is still ineffective, largely due to the immunological and physicochemical barriers of the lungs. Most studies using spray-drying for the nanoencapsulation of drugs focus on the delivery of conventional drugs, which are less susceptible to bioactivity loss, compared to proteins. Herein, the development of polymeric nanoparticles by spray-drying for the delivery of therapeutic proteins is reviewed with an emphasis on its advantages and challenges, and the techniques to evaluate their in vitro and in vivo performance. The protein stability within the carrier and the features of the carrier are properly addressed.
Collapse
Affiliation(s)
- Tânia Marante
- Center for Marine Sciences (CCMar), University of Algarve, Gambelas Campus, 8005-139 Faro, Portugal; (T.M.); (C.V.)
- Department of Chemistry and Pharmacy, Faculty of Sciences and Technology, University of Algarve, Gambelas Campus, 8005-139 Faro, Portugal
| | - Cláudia Viegas
- Center for Marine Sciences (CCMar), University of Algarve, Gambelas Campus, 8005-139 Faro, Portugal; (T.M.); (C.V.)
- Department of Chemistry and Pharmacy, Faculty of Sciences and Technology, University of Algarve, Gambelas Campus, 8005-139 Faro, Portugal
| | - Inês Duarte
- Institute for Bioengineering and Biosciences (iBB), Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal;
| | - Ana S. Macedo
- LAQV, REQUIMTE, Department of Chemical Sciences–Applied Chemistry Lab, Faculty of Pharmacy, University of Porto, Rua Jorge de Viterbo Ferreira 228, 4050-313 Porto, Portugal;
| | - Pedro Fonte
- Center for Marine Sciences (CCMar), University of Algarve, Gambelas Campus, 8005-139 Faro, Portugal; (T.M.); (C.V.)
- Department of Chemistry and Pharmacy, Faculty of Sciences and Technology, University of Algarve, Gambelas Campus, 8005-139 Faro, Portugal
- Institute for Bioengineering and Biosciences (iBB), Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal;
| |
Collapse
|
21
|
Liu P, Yang X, Han J, Zhao M, Guo J, Si R, Zhang Z, Wang A, Zhang J. Tazarotene-loaded PLGA nanoparticles potentiate deep tissue pressure injury healing via VEGF-Notch signaling. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2020; 114:111027. [PMID: 32994012 DOI: 10.1016/j.msec.2020.111027] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Revised: 04/14/2020] [Accepted: 04/27/2020] [Indexed: 02/02/2023]
Abstract
BACKGROUND AND PURPOSE New capillaries are essential for deep tissue pressure injury wound healing. Tazarotene is a recently discovered small molecule drug and functions to promote neovascularization and tissue repair. At present, the application of tazarotene in the repair of pressure injuries has not previously been investigated. This study used poly (lactic-co-glycolic acid) (PLGA) as nanoparticle carriers loaded with tazarotene (Ta/PLGA NPs) for drug delivery and to overcome shortcomings associated with the low water solubility, short half-life, easy photolysis and low bioavailability of tazarotene itself. METHODS The physicochemical properties, drug release and bioactivity of Ta/PLGA NPs were examined in vitro by transmission electron microscope, spectrophotometry and cell assays. Mouse models of deep tissue pressure injuries (DTPI) were established and the therapeutic effects and mechanisms of Ta/PLGA NPs in local wound repair were studied. RESULTS The results showed that Ta/PLGA NPs were of uniform size and distribution and were non-toxic both in vitro and in vivo. In vivo experiments suggested that Ta/PLGA NPs significantly promoted DTPI wound repair through activation of the VEGF/VEGFR-Notch1/DLL4 signaling pathway. CONCLUSION This study highlights the potential clinical significance of implementation of tazarotene small molecule drugs in combination with effective biomaterial carriers for the treatment of chronic refractory wounds, such as DTPI.
Collapse
Affiliation(s)
- Panpan Liu
- College of Nursing, Qingdao University, Qingdao, Shandong, China
| | - Xu Yang
- College of Nursing, Qingdao University, Qingdao, Shandong, China
| | - Jing Han
- College of Nursing, Qingdao University, Qingdao, Shandong, China
| | - Meng Zhao
- College of Nursing, Qingdao University, Qingdao, Shandong, China
| | - Jinglin Guo
- College of Nursing, Qingdao University, Qingdao, Shandong, China
| | - Ruijuan Si
- College of Nursing, Qingdao University, Qingdao, Shandong, China
| | - Zirui Zhang
- College of Nursing, Qingdao University, Qingdao, Shandong, China
| | - Aimin Wang
- College of Nursing, Qingdao University, Qingdao, Shandong, China
| | - Ju Zhang
- College of Nursing, Qingdao University, Qingdao, Shandong, China.
| |
Collapse
|
22
|
Nicardipine Loaded Solid Phospholipid Extrudates for the Prevention of Cerebral Vasospasms: In Vitro Characterization. Pharmaceutics 2020; 12:pharmaceutics12090817. [PMID: 32872184 PMCID: PMC7557531 DOI: 10.3390/pharmaceutics12090817] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Revised: 08/24/2020] [Accepted: 08/25/2020] [Indexed: 12/29/2022] Open
Abstract
The aim of the study was to develop nicardipine loaded phospholipid extrudates as an alternative for PLA/PLGA-based implants for the prevention of cerebral vasospasms. Extrudates of different mixtures of saturated and unsaturated phosphatidylcholine (PC) were produced and characterized by DSC, microscopy and texture analysis. Single phospholipid components were identified by ELSD-HPLC. Extrudates of 2 mm diameter were obtained by twin screw extrusion temperatures below 50 °C. The ratio of unsaturated and saturated phosphatidylcholine components determines the physicochemical properties of the extrudates as well as the rate of erosion. Nicardipine loaded phospholipids extrudates released the drug over several weeks in vitro. The phospholipid composition of the remaining extrudate changed during the release, the content of unsaturated phospholipids decreased faster compared to the saturated ones. In conclusion, solid phospholipid extrudates are promising materials for the development of new parenteral controlled release systems.
Collapse
|
23
|
Tamani F, Hamoudi MC, Danede F, Willart J, Siepmann F, Siepmann J. Towards a better understanding of the release mechanisms of caffeine from PLGA microparticles. J Appl Polym Sci 2020. [DOI: 10.1002/app.48710] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- Fahima Tamani
- Univ. Lille, Inserm, CHU Lille, U1008, Lille, F‐59000 France
| | | | - Florence Danede
- Univ. Lille, USTL UMET UMR CNRS 8207, F‐59650 Villeneuve d'Ascq France
| | | | | | | |
Collapse
|
24
|
Zech J, Leisz S, Göttel B, Syrowatka F, Greiner A, Strauss C, Knolle W, Scheller C, Mäder K. Electrospun Nimodipine-loaded fibers for nerve regeneration: Development and in vitro performance. Eur J Pharm Biopharm 2020; 151:116-126. [PMID: 32283212 DOI: 10.1016/j.ejpb.2020.03.021] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2019] [Revised: 03/27/2020] [Accepted: 03/31/2020] [Indexed: 10/24/2022]
Abstract
Nimodipine is a 1,4-Dihydropyridine type calcium antagonist routinely used to control blood pressure and reduce the risk of secondary ischemia after aneurismal subarachnoid hemorrhage. Additionally, Nimodipine has unique neuroprotective properties. With respect to brain related applications, the full potential of the desired local effect can often not be realized after systemic administration due to systemic side effects. Therefore, it was our aim to develop a biodegradable drug delivery system for the local controlled release of the drug inside the brain. As a suitable and biodegradable system we successfully electrospun PLGA fibers containing 1 and 10% drug. The results of DSC and X-Ray diffractometry measurements indicate that Nimodipine was incorporated in the polymer matrix in the amorphous state. No drug recrystallization was detected for up to 6 months. Electron-beam sterilization was tried but reduced the drug content of the fiber mats considerably. A sustained drug release over 4-8 days was observed, highly depended on release conditions. The Nimodipine fiber mats exhibited no cell toxicity. In contrast, the electrospun fibers were able to significantly reduce cell death in in vitro cell models of oxidative, osmotic and heat-induced cell stress in Schwann cells, neuronal cells as well as immortalized and primary astrocytes. Therefore, electrospun Nimodipine loaded PLGA fibers represent a promising drug delivery system to realize the druǵs benefits for its intracranial use.
Collapse
Affiliation(s)
- Johanna Zech
- Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - Sandra Leisz
- Department of Neurosurgery, University of Halle-Wittenberg, Halle (Saale), Germany
| | - Benedikt Göttel
- Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - Frank Syrowatka
- Interdisciplinary Center of Materials Science, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - Andreas Greiner
- Macromolecular Chemistry II, University of Bayreuth, Germany
| | - Christian Strauss
- Department of Neurosurgery, University of Halle-Wittenberg, Halle (Saale), Germany
| | - Wolfgang Knolle
- Leibniz Institute of Surface Engineering (IOM) Leipzig, Germany
| | - Christian Scheller
- Department of Neurosurgery, University of Halle-Wittenberg, Halle (Saale), Germany
| | - Karsten Mäder
- Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
| |
Collapse
|
25
|
Siepmann J, Siepmann F. Sink conditions do not guarantee the absence of saturation effects. Int J Pharm 2020; 577:119009. [DOI: 10.1016/j.ijpharm.2019.119009] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Revised: 12/26/2019] [Accepted: 12/29/2019] [Indexed: 11/26/2022]
|
26
|
Naseri E, Butler H, MacNevin W, Ahmed M, Ahmadi A. Low-temperature solvent-based 3D printing of PLGA: a parametric printability study. Drug Dev Ind Pharm 2020; 46:173-178. [DOI: 10.1080/03639045.2019.1711389] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Emad Naseri
- Faculty of Sustainable Design Engineering, University of Prince Edward Island, Charlottetown, Canada
| | - Haley Butler
- Faculty of Sustainable Design Engineering, University of Prince Edward Island, Charlottetown, Canada
| | - Wyatt MacNevin
- Faculty of Sustainable Design Engineering, University of Prince Edward Island, Charlottetown, Canada
| | - Marya Ahmed
- Faculty of Sustainable Design Engineering, University of Prince Edward Island, Charlottetown, Canada
| | - Ali Ahmadi
- Faculty of Sustainable Design Engineering, University of Prince Edward Island, Charlottetown, Canada
| |
Collapse
|
27
|
He Y, Qin L, Huang Y, Ma C. Advances of Nano-Structured Extended-Release Local Anesthetics. NANOSCALE RESEARCH LETTERS 2020; 15:13. [PMID: 31950284 PMCID: PMC6965527 DOI: 10.1186/s11671-019-3241-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Accepted: 12/26/2019] [Indexed: 05/08/2023]
Abstract
Extended-release local anesthetics (LAs) have drawn increasing attention with their promising role in improving analgesia and reducing adverse events of LAs. Nano-structured carriers such as liposomes and polymersomes optimally meet the demands of/for extended-release, and have been utilized in drug delivery over decades and showed satisfactory results with extended-release. Based on mature technology of liposomes, EXPAREL, the first approved liposomal LA loaded with bupivacaine, has seen its success in an extended-release form. At the same time, polymersomes has advances over liposomes with complementary profiles, which inspires the emergence of hybrid carriers. This article summarized the recent research successes on nano-structured extended-release LAs, of which liposomal and polymeric are mainstream systems. Furthermore, with continual optimization, drug delivery systems carry properties beyond simple transportation, such as specificity and responsiveness. In the near future, we may achieve targeted delivery and controlled-release properties to satisfy various analgesic requirements.
Collapse
Affiliation(s)
- Yumiao He
- Department of Anesthesiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China
- Joint Laboratory of Anesthesia and Pain, Peking Union Medical College, Beijing, 100730, China
- Department of Human Anatomy, Histology and Embryology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, 100005, China
| | - Linan Qin
- Joint Laboratory of Anesthesia and Pain, Peking Union Medical College, Beijing, 100730, China
- Department of Human Anatomy, Histology and Embryology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, 100005, China
| | - Yuguang Huang
- Department of Anesthesiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
- Joint Laboratory of Anesthesia and Pain, Peking Union Medical College, Beijing, 100730, China.
| | - Chao Ma
- Joint Laboratory of Anesthesia and Pain, Peking Union Medical College, Beijing, 100730, China.
- Department of Human Anatomy, Histology and Embryology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, 100005, China.
| |
Collapse
|
28
|
Dahmana N, Kowalczuk L, Gabriel D, Behar-Cohen F, Gurny R, Kalia YN. Ocular Biodistribution of Spironolactone after a Single Intravitreal Injection of a Biodegradable Sustained-Release Polymer in Rats. Mol Pharm 2020; 17:59-69. [PMID: 31751144 DOI: 10.1021/acs.molpharmaceut.9b00707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Sustained-release formulations for ocular delivery are of increasing interest given their potential to significantly improve treatment efficacy and patient adherence. The objectives of this study were (i) to develop a sustained-release formulation of spironolactone (SPL) using a biodegradable and injectable polymer, hexyl-substituted poly-lactic acid (hexPLA) and (ii) to investigate the ocular biodistribution and tolerability of SPL and its metabolites in rats in vivo over 1 month following a single intravitreal injection (IVT inj). The concentrations of SPL and its two principal active metabolites, 7α-thiomethylspironolactone and canrenone (CAN), in the different ocular compartments were determined at different time points (3, 7, and 31 days after IVT inj) using a validated ultra-high-performance liquid chromatography-mass spectrometry method. Systemic exposure following a single IVT inj of 5% SPL-hexPLA formulation was evaluated by quantifying SPL and its metabolites in the plasma. Ocular tolerability of the formulation was evaluated using in vivo retinal imaging and histology. In vitro release studies revealed a sustained release of SPL from 5% SPL-hexPLA for up to 65 days. In vivo studies showed that SPL and its metabolites were detected in all ocular tissues at 3 and 7 days post-IVT inj. At 31 days post-IVT inj, SPL and CAN were mainly detected in the retina. These results also highlighted the clearance pathway of SPL and its metabolite involving the anterior and posterior routes in the first week (days 3 and 7), then mainly the posterior segment in the last week (day 31). This study showed that a single IVT inj of 5% SPL-hexPLA in rats enabled sustained delivery of therapeutic amounts of SPL for up to 1 month to the retina without systemic exposure. This formulation may be of interest for the local treatment of diseases involving overactivation of the mineralocorticoid receptor in the chorioretina such as chronic central serous chorioretinopathy.
Collapse
Affiliation(s)
- Naoual Dahmana
- School of Pharmaceutical Sciences , University of Geneva & University of Lausanne , CMU-Rue Michel Servet 1 , 1211 Geneva 4 , Switzerland
| | - Laura Kowalczuk
- Faculty of Biology and Medicine , University of Lausanne , Rue du Bugnon 21 , 1011 Lausanne , Switzerland.,Jules-Gonin Eye Hospital, Fondation Asile des Aveugles , Avenue de France 15 , 1004 Lausanne , Switzerland
| | - Doris Gabriel
- Apidel SA , Quai du Mont Blanc 29 , 1201 Geneva , Switzerland
| | - Francine Behar-Cohen
- Faculty of Biology and Medicine , University of Lausanne , Rue du Bugnon 21 , 1011 Lausanne , Switzerland.,Centre de Recherche des Cordeliers, Université de Paris , INSERM U1138, Team Physiopathology of Ocular Diseases: Therapeutic Innovations, Paris , France.,Hôpital Cochin - Assistance Publique Hôpitaux de Paris , Ophtalmopole , Paris , France
| | - Robert Gurny
- School of Pharmaceutical Sciences , University of Geneva & University of Lausanne , CMU-Rue Michel Servet 1 , 1211 Geneva 4 , Switzerland.,Apidel SA , Quai du Mont Blanc 29 , 1201 Geneva , Switzerland
| | - Yogeshvar N Kalia
- School of Pharmaceutical Sciences , University of Geneva & University of Lausanne , CMU-Rue Michel Servet 1 , 1211 Geneva 4 , Switzerland
| |
Collapse
|
29
|
Lizambard M, Menu T, Fossart M, Bassand C, Agossa K, Huck O, Neut C, Siepmann F. In-situ forming implants for the treatment of periodontal diseases: Simultaneous controlled release of an antiseptic and an anti-inflammatory drug. Int J Pharm 2019; 572:118833. [PMID: 31715363 DOI: 10.1016/j.ijpharm.2019.118833] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Revised: 10/23/2019] [Accepted: 10/28/2019] [Indexed: 01/16/2023]
Abstract
Different types of in-situ forming implants based on poly(lactic-co-glycolic acid) (PLGA) for the controlled dual release of an antiseptic drug (chlorhexidine) and an anti-inflammatory drug (ibuprofen) were prepared and thoroughly characterized in vitro. N-methyl-pyrrolidone (NMP) was used as water-miscible solvent, acetyltributyl citrate (ATBC) as plasticizer and hydroxypropyl methylcellulose (HPMC) was added to enhance the implants' stickiness/bioadhesion upon formation within the periodontal pocket. Different drug forms exhibiting substantially different solubilities were used: chlorhexidine dihydrochloride and digluconate as well as ibuprofen free acid and lysinate. The initial drug loadings were varied from 1.5 to 16.1%. In vitro drug release, dynamic changes in the pH of the surrounding bulk fluid and in the systems' wet mass as well as polymer degradation were monitored. Importantly, the release of both drugs, chlorhexidine and ibuprofen, could effectively be controlled simultaneously during several weeks. Interestingly, the tremendous differences in the drug forms' solubilities (e.g., factor >5000) did not translate into major differences in the resulting release kinetics. In the case of ibuprofen, this can likely (at least in part) be attributed to significant drug-polymer interactions (ibuprofen acts as a plasticizer for PLGA). In the case of chlorhexidine, the release of the much less soluble dihydrochloride was even faster compared to the more soluble digluconate (when combined with ibuprofen free acid). In the case of ibuprofen, at higher initial drug loadings also limited solubility effects within the implants seem to play a role, in contrast to chlorhexidine. In the latter case, instead, increased system porosity effects likely dominate at higher drug loadings.
Collapse
Affiliation(s)
- M Lizambard
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - T Menu
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - M Fossart
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - C Bassand
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - K Agossa
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - O Huck
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie-dentaire, 8 rue Sainte-Elisabeth, 67000 Strasbourg, France
| | - C Neut
- Univ. Lille, Inserm, CHU Lille, U995-LIRIC, F-59000 Lille, France
| | - F Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France.
| |
Collapse
|